Oppenheimer Analyst Predicts 740% Upside for THIS Little Known Stock... (What Do They Know?)

Well it’s no secret that the market has been on a tear lately. Inflation’s cooling off (finally), clocking in at 2.4%—just a hair shy of the Fed’s 2% target. Meanwhile, all three major indexes are popping with the Nasdaq leading 24.22% YTD. A.k.a. not bad for an economy that was supposed to be on the verge of collapse per all the overpaid analysts at JPMorgan, amirite?

(Source: Reddit) 

Meaning, the doomsday predictions are starting to age like old milk, and Oppenheimer’s analysts are prime examples of this. How, you ask? Well because they are not only doubling down on equities, but they’re also calling for a 740% upside on one particular stock you’ve likely never heard of.  

(Source: Tip Ranks) 

The stock in question? Rani Therapeutics (RANI). And before you roll your eyes because you've never heard of it, bare with me… because there’s definitely something in the making here. 

In short, Rani Therapeutics is doing what no one thought possible—making biologic drugs, which normally need a needle or an IV, something you can pop like a pill. Simply put, while most biologics are used to treat some of the nastiest autoimmune, inflammatory, and metabolic diseases out there - these drugs are usually delivered via IV infusions because they can’t survive the stomach’s acid bath. Meaning, this is a huge pain point (literally and figuratively) for patients.

(Source: Giphy) 

However, now, with Rani’s “RaniPill”, this capsule can survive the hostile environment of your stomach and deliver biologic drugs directly to your small intestine. Translation: no more needles, no more IVs, just effective treatment without the drama (a.k.a. an absolute beast of a game changer within a $500+ billion global biologics market). 

(Source: Giphy) 

In addition, Rani’s pipeline isn’t just another boring lineup of “maybe” drugs, either. We’re talking about real contenders here. For instance, their lead product, RT-102, is heading into Phase 2 trials in Europe by the end of this year for osteoporosis. Another promising drug, RT-111, aimed at psoriasis, is moving up the ranks after some solid Phase 1 results. And if that wasn’t enough, they’ve teamed up with ProGen to tackle obesity with RT-114, set to enter Phase 1 trials in 2025. 

(Source: Rani Therapeutics) 

Now ICYMI, companies like Eli Lilly and Novo Nordisk have made obesity/diabetic medications (see: GLP-1s) the second most popular Wall Street buzz word of 2024 (right behind AI). However, just like the pain of IV and needles for biologic medications, GLP-1s can only be taken with injections. Meaning, with Rani’s weekly RT-113 pill that damn near has the same goal and impact as its “injectable competitors”, we could be seeing a major blockbuster drug in the making. 

Which is why, Oppenheimer’s analyst Andreas Argyrides is not holding back on this one. He’s calling Rani a “pioneer in the oral biologics space” and slapping a Buy rating on it with a price target of $17. For context, Rani’s stock is currently chilling at just over $2. That’s where the 740% upside potential comes in. If they hit their targets, this could be the ultimate needle in the haystack story. 

For instance, Argyrides is bullish on the idea that Rani’s RaniPill could rake in $1.1 billion in product revenue just by making biologics more accessible. Imagine being able to take a once-weekly pill for conditions like osteoporosis or obesity—without the hassle of injections. That’s huge. Especially with the global biologics market projected to hit $845 billion by 2033. 

(Source: Yahoo Finance) 

What’s more is that due to the fact that Rani’s got its foot in the door, with massive potential upside ahead, insiders have taken notice. For example, Jean-Luc Butel, one of Rani’s independent directors, just dropped over $100k at around $2 a pop. 

Which honestly, doesn’t seem like much, but let’s say Rani’s stock does hit its 740% target… Butel will be sitting pretty with a nice $840,000 windfall. And like always, when insiders are putting their money where their mouth is, you know something’s brewing. 

(Source: Yahoo Finance) 

On the other hand though, even with all the hype and the promising potential Rani Therapeutics holds in its arsenal, the stock definitely doesn’t come without its risks. In fact, so far this year, Rani’s stock has absolutely taken a beating, down -40% YTD. However, with Phase 2 trials on the horizon and a boatload of potential catalysts, it’s looking like an impressive “BTFD” opportunity - especially as Rani’s stock catapulted 13.37% on Friday alone. Plus, the fact that Oppenheimer is predicting a rally of over 700%? That’s not something you hear every day. 

(Source: Giphy) 

So clearly all the pieces are there, but still Rani is a high-risk, high-reward play. So if you’re looking for a stock to gamble some play money on… this might be it (please act accordingly). As Argyrides put it, Rani’s innovation in oral biologics is a “game-changer”—and with the stock trading at a bargain, now might be time to start paying attention. 

In the meantime, regardless of what you do, it might be worth keeping an eye on the stock and running some numbers to see if this play is right for you. And as always, stay safe and stay frosty this Monday, friends! Until next time… 

P.S. I know It’s Monday, so I’ll make this quick. We've successfully predicted up to 16 triple-digit (100% or more) opportunities nearly every single week for the past four months... and our next alert is set to be released early next week. Meaning, if you haven't done so yet, I'd highly suggest clicking here ASAP and joining the 2,000+ Stocks.News Premium Members.

Stocks.News does not hold any positions in companies mentioned in the article.